IP Library › Granted Patent US 11,718,656
Granted Patent B2
US 11,718,656 · App. 17/830,773 · Granted Aug 8, 2023

Inducible caspases and methods for use

Inventors: Eric M. Ostertag (Lexington, KY); Devon Shedlock (San Diego, CA)
Assignee: Poseida Therapeutics, Inc.
C07K14/705A61K35/17A61P3/00A61P17/02A61P29/00A61P31/00A61P35/00A61P37/00C07K14/47C07K14/4747C12N5/0636C12N9/50C12N15/52C12Y304/22036
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,718,656
App. No.
17/830,773
Granted
Aug 8, 2023
Kind
B2
Abstract

The disclosure provides inducible caspase polypeptides, compositions comprising inducible caspase polypeptides and sequences encoding the same, cells modified to express the polypeptides and compositions of the disclosure, as well as methods of making and methods of using same for adoptive cell therapy.

Claims (10)

1. A polynucleotide comprising the nucleic acid sequence of SEQ ID NO: 10.

2. A transposon comprising the polynucleotide of claim 1 .

3. The transposon of claim 2 , further comprising a nucleic acid sequence encoding a therapeutic protein.

4. The transposon of claim 3 , wherein the therapeutic protein comprises an antigen receptor, a cell surface protein, a membrane-bound protein, an extracellular membrane-bound protein, an intracellular membrane-bound protein, an intracellular protein, a nuclear localized protein, a nuclear protein, a cytoplasmic protein, a cytosolic protein, a secreted protein, a lysosomal protein, an endosomal protein, a vesicle-associated protein, a mitochondrial protein, an endoplasmic reticulum protein, a cytoskeletal protein, a protein involved in intracellular signaling, a protein involved in extracellular signaling, or any combination thereof.

5. The transposon of claim 4 , wherein the antigen receptor comprises a T-Cell Receptor (TCR) or a Chimeric Antigen Receptor (CAR).

6. The transposon of claim 2 , wherein the transposon is a piggyBac transposon, a Sleeping Beauty transposon, a Helraiser transposon, or Tol2 transposon.

7. A vector comprising the polynucleotide of claim 1 .

8. A cell comprising the polynucleotide of claim 1 .

9. The cell of claim 8 , wherein the cell is a human cell, an immune cell, an artificial antigen presenting cell, a stem cell, or any combination thereof.

10. A composition comprising the cell of claim 9 .

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 3, 2022
From: OSTERTAG, ERIC M.; SHEDLOCK, DEVON
To: POSEIDA THERAPEUTICS, INC.
Reel/Frame 060092/0708 →
Continuity (3)
Division 16339710
Provisional Application 62405184 · Oct 6, 2016
Related Publication 20230002469A1 · Jan 5, 2023